Results 161 to 170 of about 381,827 (331)

Motion Mitigation Techniques for Abdominal and Cardiac MR Imaging

Journal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT MRI of the heart and abdominal organs provides unparalleled soft tissue contrast and quantitative biomarkers, yet remains highly susceptible to physiological motion. Contractions of the myocardium, respiratory excursions, peristalsis, vascular pulsatility, and unpredictable bulk patient movement generate artifacts that impair image quality ...
Eric M. Schrauben, Gastao Lima da Cruz, Christopher W. Roy, Thomas Küstner   +3 more
wiley   +1 more source

Network pharmacology reveals Ficus. Carica. L latex as a potential therapeutic agent for gastric ulcers by modulating inflammation and promoting repair. [PDF]

PLoS One
Shady NH, Hisham M, Abdullah HS, Maher SA, Albohy A, Elrehany MA, Sayed AM, Allehyani ES, Khowdiary MM, Shawky AM, Abdelmohsen UR.   +10 more
europepmc   +1 more source

Effects of a Novel Anti-ulcer Agent Tocoretinate on Acute, Subacute or Chronic Ulcer Models in Rats and Dogs.

, 1991
Yoshikazu Masukawa, Yosuke Urano, Hiroyuki Hamada, Kumi Shirogane, Katsuyuki Nishiki, Hidetoshi Takagi, Yasuo Furukawa, Akira Sato, Shigeru Asaki   +8 more
openalex   +1 more source

Research progress on hyperbaric oxygen therapy for refractory peptic ulcer disease. [PDF]

Front Med (Lausanne)
Chen ZM, Li WF, Yu XQ, Tang X, Yang QH, Wei XL.   +5 more
europepmc   +1 more source

Effects of KP-105, a novel anti-ulcer agents, on various ulcer models

, 1997
Masahiro Fujil, Yuli Fukamizu, Nobuko Itoh, Tsutomu Nakajima, Yoshiyuki Hata, Kunio Kimura   +5 more
openalex   +1 more source

Peptic ulcer and non-steroidal anti-inflammatory agents. [PDF]

, 1986
J. M. Duggan, Annette J. Dobson, H. Daintree Johnson, Paul Fahey   +3 more
openalex   +1 more source

Reshaping study design for faster extrapolation‐based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN–NASPGHAN position paper

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Children with inflammatory bowel diseases (IBD) have limited access to the available advanced therapies, given the lengthy gap between adult and pediatric approval. We aimed to review key hurdles for pediatric trials and recommend practical solutions.
Dan Turner, Amit Assa, Mikkel Malham, Shira Yuval Bar‐Asher, Carla Rayan, Jeffrey S. Hyams, Holm H. Uhlig, Brad Pasternak, David C. Wilson, Hilary K. Michel, Lissy de Ridder, Eric Zuckerman, Marina Aloi, Peter Szitanyi, Marla C. Dubinsky, Anne M. Griffiths, Roberto Saldana, Javier Martín‐de‐Carpi, Eytan Wine, Richard K. Russell, Jeremy Adler, Joseph Picoraro   +21 more
wiley   +1 more source

The Gastroprotective Effect of Hydrogen-Rich Coral Calcium in a Mouse Model of Peptic Ulcer Disease. [PDF]

Drug Des Devel Ther
Wu HT, Hsieh MT, Ou HY, Chao TH, Tsai LM.   +4 more
europepmc   +1 more source

Pharmacokinetics of a novel anti-ulcer agent, Z-300 and its action on intragastrine pH.

, 1994
Kazuo Umemura
openalex   +2 more sources

Vedolizumab for extraintestinal manifestations in pediatric inflammatory bowel disease: Results from the VedoKids study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Extraintestinal manifestations (EIMs) manifest in 6%‐47% of patients with inflammatory bowel disease (IBD). Here, we characterize the course of EIMs in pediatric patients receiving vedolizumab included in the VedoKids cohort study. This was a subgroup analysis of the pediatric VedoKids cohort, a multicenter, prospective study of children (aged
Giulia D'Arcangelo, Dan Turner, Oren Ledder, Esther Orlanski‐Meyer, Efrat Broide, Maya Granot, Manar Matar, Seamus Hussey, Anat Yerushalmy‐Feler, Christoph Norden, Erasmo Miele, Marina Aloi   +11 more
wiley   +1 more source